MA33447B1 - Nouveau composé utilisé pour traiter les maladies dégénératives et inflammatoires - Google Patents

Nouveau composé utilisé pour traiter les maladies dégénératives et inflammatoires

Info

Publication number
MA33447B1
MA33447B1 MA34555A MA34555A MA33447B1 MA 33447 B1 MA33447 B1 MA 33447B1 MA 34555 A MA34555 A MA 34555A MA 34555 A MA34555 A MA 34555A MA 33447 B1 MA33447 B1 MA 33447B1
Authority
MA
Morocco
Prior art keywords
compound used
inflammatory diseases
novel compound
diseases
treat degenerative
Prior art date
Application number
MA34555A
Other languages
Arabic (ar)
English (en)
Inventor
Christel Jeanne Marie Menet
Javier Blanc
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of MA33447B1 publication Critical patent/MA33447B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

L'invention concerne un composé représenté par la formule (I). Ce composé peut être préparé comme une composition pharmaceutique, et peut être utilisé pour prévenir et traiter une variété d'états chez les mammifères, en particulier chez l'homme, comprenant à titre d'exemple notamment et de manière non restrictive, les états inflammatoires, les maladies auto-immunes, les maladies prolifératives, les rejets de transplantation, les maladies impliquant l'incapacité de renouvellement du cartilage, les malformations congénitales du cartilage, et/ou les maladies associées à l'hypersécrétion de IL6.
MA34555A 2009-06-26 2010-06-25 Nouveau composé utilisé pour traiter les maladies dégénératives et inflammatoires MA33447B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22068509P 2009-06-26 2009-06-26
US29818810P 2010-01-25 2010-01-25
PCT/EP2010/059067 WO2010149771A1 (fr) 2009-06-26 2010-06-25 Nouveau composé utilisé pour traiter les maladies dégénératives et inflammatoires

Publications (1)

Publication Number Publication Date
MA33447B1 true MA33447B1 (fr) 2012-07-03

Family

ID=42340530

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34555A MA33447B1 (fr) 2009-06-26 2010-06-25 Nouveau composé utilisé pour traiter les maladies dégénératives et inflammatoires

Country Status (37)

Country Link
US (2) US8796457B2 (fr)
EP (2) EP2792677B1 (fr)
JP (1) JP5486084B2 (fr)
KR (1) KR101712561B1 (fr)
CN (1) CN102459261B (fr)
AR (1) AR077221A1 (fr)
AU (1) AU2010264635B2 (fr)
BR (1) BRPI1014759A2 (fr)
CA (1) CA2765988C (fr)
CL (1) CL2011003276A1 (fr)
CO (1) CO6491039A2 (fr)
CR (1) CR20110673A (fr)
CY (1) CY1119711T1 (fr)
DK (2) DK2792677T3 (fr)
DO (1) DOP2011000378A (fr)
EA (1) EA020111B1 (fr)
ES (2) ES2519170T3 (fr)
HR (2) HRP20141057T1 (fr)
HU (1) HUE034205T2 (fr)
IL (1) IL216618A (fr)
JO (1) JO3030B1 (fr)
LT (1) LT2792677T (fr)
MA (1) MA33447B1 (fr)
ME (1) ME01916B (fr)
MX (1) MX2011013451A (fr)
NZ (1) NZ596836A (fr)
PE (1) PE20120494A1 (fr)
PL (2) PL2445912T3 (fr)
PT (2) PT2445912E (fr)
RS (1) RS53617B1 (fr)
SG (1) SG177359A1 (fr)
SI (2) SI2445912T1 (fr)
SM (2) SMT201700333T1 (fr)
TW (1) TWI469981B (fr)
UY (1) UY32741A (fr)
WO (1) WO2010149771A1 (fr)
ZA (1) ZA201109502B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3041B1 (ar) 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
US8637038B2 (en) 2011-04-12 2014-01-28 Rigel Pharmaceuticals, Inc. Methods for inhibiting allograft rejection
SG10201914052TA (en) * 2011-10-11 2020-03-30 Sanofi Biotechnology Compositions for the treatment of rheumatoid arthritis and methods of using same
TWI589299B (zh) * 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
US9284311B2 (en) * 2012-06-22 2016-03-15 Galapagos Nv Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof
PE20161323A1 (es) 2013-09-05 2016-11-25 Hoffmann La Roche Compuestos de triazolopiridina, composiciones y metodos de uso de los mismos
SI3077395T1 (en) 2013-12-05 2018-03-30 Pfizer Inc. Pyrrolo(2,3-d)pyrimidinyl, pyrrolo(2,3-b)pyrazinyl and pyrrolo(2,3-d)pyridinyl acrylamides
GB201402070D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
GB201402071D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
US10376520B2 (en) * 2015-04-13 2019-08-13 Galapagos Nv Methods for the treatment of cardiovascular disorders
KR102598246B1 (ko) 2016-07-26 2023-11-02 톈진 롱보진 파마시우티컬 씨오., 엘티디. Jak 저해제로서 헤테로사이클릭 화합물, 및 이의 염 및 치료학적 용도
CN111479810B (zh) 2018-01-31 2022-11-22 珠海联邦制药股份有限公司 Jak抑制剂及其应用
SG11202101674QA (en) 2018-08-29 2021-03-30 Regeneron Pharma Methods and compositions for treating subjects having rheumatoid arthritis
MA54861A (fr) 2019-01-31 2021-12-08 Regeneron Pharma Anticorps anti-récepteur de l'il6 pour traiter l'arthrite idiopathique juvénile
SG11202111742QA (en) 2019-04-24 2021-11-29 Sanofi Biotechnology Methods of diagnosis and treatment of rheumatoid arthritis
CA3142710A1 (fr) 2019-06-04 2020-12-10 Sanofi Biotechnology Compositions et procedes de traitement de la douleur chez des sujets atteints de polyarthrite rhumatoide
CN111072655B (zh) * 2019-12-30 2021-12-10 深圳市坤健创新药物研究院 一种三氮唑并吡啶类化合物及其制备方法和药用组合物与应用
US12240813B2 (en) 2020-05-19 2025-03-04 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
US11596612B1 (en) 2022-03-08 2023-03-07 PTC Innovations, LLC Topical anesthetics

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1156037B1 (fr) 1999-01-29 2004-12-01 Chugai Seiyaku Kabushiki Kaisha Promoteurs de la chondrogenese et derives d'indolin-2-one
JPWO2002087620A1 (ja) 2001-04-27 2004-08-12 中外製薬株式会社 軟骨形成促進剤
US6514989B1 (en) * 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
JP2005528443A (ja) * 2002-05-30 2005-09-22 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｊａｋキナーゼおよびｃｄｋ２プロテインキナーゼのインヒビター
EP1601672B1 (fr) 2003-02-14 2006-07-26 Pfizer Products Inc. Triazolo-pyridines utilisees comme composes anti-inflammatoires
US20050222171A1 (en) * 2004-01-22 2005-10-06 Guido Bold Organic compounds
JP2008503712A (ja) 2004-06-21 2008-02-07 ガラパゴス・ナムローゼ・フェンノートシャップ 骨関節炎治療の方法及び手段
US20090209577A1 (en) 2004-08-18 2009-08-20 Pfizer Inc. Novel Triazolopyridine Compounds
EP1799680A2 (fr) 2004-10-07 2007-06-27 Warner-Lambert Company LLC Derives de triazolopyridine comme agents antibacteriens
GB0515026D0 (en) 2005-07-21 2005-08-31 Novartis Ag Organic compounds
BRPI0716239A2 (pt) * 2006-08-30 2013-08-13 Cellzome Ltd derivados de triazol como inibidores de cinase
CL2008001626A1 (es) 2007-06-05 2009-06-05 Takeda Pharmaceuticals Co Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer.
CA2693232A1 (fr) 2007-07-18 2009-01-22 Novartis Ag Composes heteroaryliques bicycliques et leur utilisation comme inhibiteurs de kinase
WO2009017954A1 (fr) * 2007-08-01 2009-02-05 Phenomix Corporation Inhibiteurs de kinase jak2
CA2691448A1 (fr) 2007-08-31 2009-03-05 Dominique Swinnen Composes de triazolopyridine et leur utilisation comme inhibiteurs de ask
GB0719803D0 (en) * 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
US20090217316A1 (en) * 2008-02-22 2009-08-27 Binita Gupta Systems and Methods for Advertising Insertion Notification in a Real-Time Streaming Media Service
WO2009155565A1 (fr) 2008-06-20 2009-12-23 Genentech, Inc. Composés triazolopyridine inhibiteurs de jak kinase et procédés
WO2010010189A1 (fr) 2008-07-25 2010-01-28 Galapagos Nv Nouveaux composés utiles pour le traitement de maladies dégénératives et inflammatoires
JO3041B1 (ar) * 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
WO2010010184A1 (fr) 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4]triazolo[1, 5-a]pyridines utilisées comme inhibiteurs de jak
WO2010010186A1 (fr) * 2008-07-25 2010-01-28 Galapagos Nv Nouveaux composés utiles pour le traitement de maladies dégénératives et inflammatoires
WO2010010188A1 (fr) 2008-07-25 2010-01-28 Galapagos Nv Nouveaux composés utiles pour le traitement de maladies dégénératives et inflammatoires
WO2010010187A1 (fr) 2008-07-25 2010-01-28 Galapagos Nv Nouveaux composés utiles pour le traitement de maladies dégénératives et inflammatoires
EP2438066A2 (fr) 2009-06-05 2012-04-11 Cephalon, Inc. Préparation et utilisation de dérivés de 1,2,4-triazolo[1,5a]pyridine
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات

Also Published As

Publication number Publication date
UY32741A (es) 2011-01-31
CL2011003276A1 (es) 2012-08-31
US9505754B2 (en) 2016-11-29
SI2792677T1 (sl) 2017-08-31
HK1202537A1 (en) 2015-10-02
ES2519170T3 (es) 2014-11-06
HUE034205T2 (en) 2018-01-29
NZ596836A (en) 2013-02-22
EP2792677B1 (fr) 2017-04-26
SG177359A1 (en) 2012-02-28
PL2445912T3 (pl) 2015-02-27
WO2010149771A1 (fr) 2010-12-29
DK2445912T3 (da) 2014-11-10
ES2634325T3 (es) 2017-09-27
IL216618A (en) 2014-09-30
ME01916B (me) 2015-05-20
DK2792677T3 (en) 2017-07-10
EA020111B1 (ru) 2014-08-29
CR20110673A (es) 2012-02-09
EP2445912B1 (fr) 2014-08-13
US8796457B2 (en) 2014-08-05
IL216618A0 (en) 2012-02-29
ZA201109502B (en) 2012-09-26
PT2792677T (pt) 2017-07-06
SMT201400169B (it) 2015-01-15
CY1119711T1 (el) 2018-06-27
AR077221A1 (es) 2011-08-10
PE20120494A1 (es) 2012-05-17
SMT201700333T1 (it) 2017-09-07
BRPI1014759A2 (pt) 2016-04-19
CO6491039A2 (es) 2012-07-31
AU2010264635A1 (en) 2011-12-22
TW201103937A (en) 2011-02-01
CA2765988A1 (fr) 2010-12-29
US20150031671A1 (en) 2015-01-29
DOP2011000378A (es) 2012-02-15
JP5486084B2 (ja) 2014-05-07
KR20120059487A (ko) 2012-06-08
HK1168098A1 (en) 2012-12-21
PT2445912E (pt) 2014-11-07
MX2011013451A (es) 2012-04-30
JO3030B1 (ar) 2016-09-05
AU2010264635B2 (en) 2015-05-07
SI2445912T1 (sl) 2014-12-31
TWI469981B (zh) 2015-01-21
JP2012530767A (ja) 2012-12-06
CN102459261A (zh) 2012-05-16
US20100331359A1 (en) 2010-12-30
HRP20171024T1 (hr) 2017-10-06
CA2765988C (fr) 2017-08-29
HRP20141057T1 (en) 2015-03-13
EP2445912A1 (fr) 2012-05-02
PL2792677T3 (pl) 2017-09-29
KR101712561B1 (ko) 2017-03-06
EP2792677A1 (fr) 2014-10-22
CN102459261B (zh) 2014-11-05
LT2792677T (lt) 2017-07-25
RS53617B1 (sr) 2015-04-30
EA201270076A1 (ru) 2012-08-30

Similar Documents

Publication Publication Date Title
MA33447B1 (fr) Nouveau composé utilisé pour traiter les maladies dégénératives et inflammatoires
MA33448B1 (fr) 5-phenyl-[1,2,4]triazolo[1,5-a]pyridin-2-yl-carboxamides utilises en tant qu'inhibiteurs de jak
MX2013012281A (es) Compuesto novedoso util para el tratamiento de enfermedades degenerativas e inflamatorias.
MA20150065A1 (fr) Nouveaux dérivés d'acide indanyloxydihydrobenzofurannylacétique et leur utilisation comme agonistes du récepteur gpr40
EP2086540B8 (fr) Composés de triazolopyridine pour le traitement de maladies dégénératives et inflammatoires
MA35153B1 (fr) Immunoconjugués, compositions les contenant, et procédés de préparation et d'utilisation correspondants
MX354134B (es) Derivados de acido 1,2,3,4-tetrahidrociclopenta [b] indol-3-il) acetico sustituidos utiles en el tratamiento de enfermedades autoinmune e inflamatorias.
MA35419B1 (fr) Inhibiteurs de la tyrosine kinase de bruton
EP4265254A3 (fr) Composés d' imidazo[4,5-b]pyridine et compositions pharmaceutiques les contenant destinés à traiter les troubles inflammatoires
BRPI0606476A2 (pt) compostos para inflamação e usos imuno-relacionados e suas composições farmacêuticas
MX2009013733A (es) Nuevos derivados de acido dicarboxilico como agonistas de los receptores de s1p1.
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
MA37775A1 (fr) Aminotriazolopyridine pour l'utilisation dans le traitement de l'inflammation, et compositions pharmaceutiques associées
WO2008061724A3 (fr) Compositions innovantes
MA41238A (fr) Dérivés 5-[(pipérazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione en tant qu'inhibiteurs d'adamts pour le traitement de l'ostéoarthrit
MX2012002641A (es) Inhibidores de cinasa janus (jak).
EP4249070A3 (fr) Dérivés hétéroaryle bicycliques utilisés en tant qu'inhibiteurs de l'ectonucléotide pyrophosphatase/phosphodiestérase 1
BR112014003063A2 (pt) "3,4-di-hidro-1h-[1,8]naftiridinonas substituídas com ciclopenta[c]pirrol antibacterianas, composição farmacêutica compreendendo os referidos compostos, processos para preparação destes e uso".
TW201613873A (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
ATE500236T1 (de) Mit lanthionin verwandte verbindungen zur behandlung entzündlicher krankheiten
MX349788B (es) Peptidomimeticos fijados a plantilla como inhibidores de receptor de formil-peptido 1.
PH12019501853A1 (en) Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2011112535A3 (fr) Acides propioniques, esters d'acides propioniques et composés apparentés
MA35102B1 (fr) Dérivés d'acide 7-(hétéroaryl-amino)-6,7,8,9-tétrahydropyrido[1,2-a]indolacétique et leur utilisation en tant que modulateurs du récepteur aux prostaglandines d2
WO2009007827A3 (fr) Nouveaux esters de diclofénac et utilisations de ceux-ci